Form 4: BioLife Solutions Exec Sells Shares for Tax Obligations

Karen A. Foster, Chief Quality and Operations at BioLife Solutions, sold 511 shares of common stock for $26.83 per share to cover tax withholding obligations.

Summary

• Karen A. Foster, Chief Quality and Operations of BIOLIFE SOLUTIONS INC (BLFS), reported a sale of common stock.
• The transaction involved the disposition of 511 shares of common stock.
• The shares were sold at a price of $26.83 per share.
• The sale occurred on September 11, 2025.
• Following this transaction, Karen A. Foster beneficially owns 193,672 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on March 8, 2024.
• The purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale for tax withholding purposes, which typically has a neutral impact on market sentiment regarding the company's fundamentals or future prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale reported herein was made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person effective as of March 8, 2024, to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Industry Context

Sales of company stock by executives to cover tax withholding obligations upon the vesting of restricted stock are a common and routine practice across various industries, often pre-arranged through Rule 10b5-1 trading plans to avoid accusations of insider trading.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not indicative of a change in management's confidence or company fundamentals.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax obligations associated with restricted stock vesting. Such transactions, especially when conducted under a Rule 10b5-1 plan, do not typically signal a change in the company's fundamental outlook or management's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate unless other fundamental factors dictate otherwise.

Keywords

BIOLIFE SOLUTIONS, BLFS, Form 4, Insider Transaction, Stock Sale, Executive Compensation, Tax Withholding, 10b5-1 Plan